Alnylam Releases New Data from Failed Phase IIb Study of RSV Drug
September 06, 2012
Alnylam Releases New Data from Failed Phase IIb Study of RSV Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013 / Gene Silencing News - Alnylam Adding Patients to ATTR Trial, Conducting Interim Analysis of RSV Data
May 5, 2011 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 21, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 21, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News